![Matthew Shair](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Matthew Shair
Corporate Officer/Principal bij
Harvard University
Vermogen: 174 M $ op 31-05-2026
Profiel
Matthew D.
Shair was the founder of Infinity Pharmaceuticals, Inc., founded in 1995, and Nuvalent, Inc., founded in 2017, where he held the title of Director from 2017 to 2025.
Dr. Shair is also the founder of Chemiderm, Inc.,Makoto Life Sciences, Inc...
Dr. Shair currently holds the position of Professor at Harvard University since 1997.
Additionally, Dr. Shair is an Associate at Harvard Stem Cell Institute and an Associate at The Broad Institute, Inc. Dr. Shair completed undergraduate education at Rochester Christian University, graduate education at Yale University, and earned a doctorate from The Trustees of Columbia University in The City of New York.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 24-11-2025 | 1.578.866 ( 2,35% ) | 174 M $ | 31-05-2026 |
Actieve functies van Matthew Shair
| Bedrijven | Functie | Begin |
|---|---|---|
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01-06-1997 |
Harvard Stem Cell Institute
 Harvard Stem Cell Institute BiotechnologyHealth Technology Provides research regarding stem cells necessary for the understanding of human development and disease and trains next generation stem cell scientists | Corporate Officer/Principal | - |
The Broad Institute, Inc.
 The Broad Institute, Inc. BiotechnologyHealth Technology Engages in research and development in bio medicals to cure infectious disease, cancer, psychiatric research and cardiovascular diseases | Corporate Officer/Principal | - |
Eerdere bekende functies van Matthew Shair
| Bedrijven | Functie | Einde |
|---|---|---|
| NUVALENT, INC. | Oprichter | 09-12-2025 |
Chemiderm, Inc. | Oprichter | - |
Makoto Life Sciences, Inc. | Oprichter | - |
| INFINITY PHARMACEUTICALS, INC. | Oprichter | - |
Opleiding van Matthew Shair
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
98
Eerstegraads connecties
10
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 10 |
|---|---|
Rochester Christian University
 Rochester Christian University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Trustees of Columbia University in The City of New York
 The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Infinity Pharmaceuticals, Inc.
 Infinity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops medicines for the treatment of cancer | Health Technology |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology Engages in research and development in bio medicals to cure infectious disease, cancer, psychiatric research and cardiovascular diseases | Health Technology |
Harvard Stem Cell Institute
Harvard Stem Cell Institute BiotechnologyHealth Technology Provides research regarding stem cells necessary for the understanding of human development and disease and trains next generation stem cell scientists | Health Technology |
Chemiderm, Inc. | |
Nuvalent, Inc.
 Nuvalent, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of targeted therapies for patients with cancer | Health Technology |
Makoto Life Sciences, Inc. |
